Bayer wins battle for Nexavar against Natco; will it win the war?
HONG KONG – An Indian court has banned exports of a generic cancer drug, giving Bayer Healthcare Pharmaceuticals Inc. a first victory in an ongoing lawsuit to protect the patent of targeted cancer drug Nexavar (sorafenib), one of its star performers co-developed with Onyx Pharmaceuticals Inc.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST